Fusion Pharmaceuticals Inc represents a commitment to advancing targeted alpha therapies to improve the lives of cancer patients. The company values innovation, collaboration, and scientific excellence in its pursuit of developing radiopharmaceuticals for the treatment of solid tumors. Fusion Pharmaceuticals believes in harnessing the power of precision medicine and next-generation radiopharmaceuticals to provide more effective and safer cancer therapies. With a focus on enhancing patient outcomes, Fusion Pharmaceuticals aims to revolutionize cancer treatment by delivering highly targeted radiation directly to tumor cells, minimizing damage to healthy tissues.

Fusion Pharmaceuticals Inc is primarily present in various countries and regions across the globe. As a leading biopharmaceutical company, Fusion Pharmaceuticals Inc operates in key marketplaces such as the United States, Canada, Europe, and Asia. With its innovative radiopharmaceutical platform, Fusion Pharmaceuticals Inc aims to revolutionize the treatment of cancer by delivering targeted alpha-emitting radiopharmaceuticals. With its presence in multiple countries and regions, Fusion Pharmaceuticals Inc is dedicated to expanding access to its cutting-edge therapies worldwide and providing hope to patients suffering from cancer.

Fusion Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) and began trading on the Nasdaq under the ticker symbol FUSN. Fusion Pharmaceuticals also secured strategic partnerships with various pharmaceutical companies, allowing them to advance their targeted alpha therapeutics. Additionally, the company received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, FPI-1434, for the treatment of solid tumors. Fusion Pharmaceuticals Inc continues to progress in its mission to develop next-generation radiopharmaceuticals for cancer treatment.

Fusion Pharmaceuticals Inc. is a biopharmaceutical company that specializes in targeted alpha therapies for the treatment of cancer. Founded in 2014, Fusion Pharma has rapidly emerged as a leader in the field, leveraging its innovative radiotherapeutics platform to develop novel treatments. The company combines alpha particle emitting isotopes with targeting molecules, enabling precise delivery of radiation directly to cancer cells while sparing healthy tissues. Fusion Pharma's mission is to revolutionize cancer therapy by developing highly effective and well-tolerated treatments that can improve patient outcomes. With a strong focus on research and development, Fusion Pharmaceuticals continues to advance its pipeline and explore new therapeutic opportunities to address unmet medical needs in oncology.

The main competitors of Fusion Pharmaceuticals Inc in the market include Pfizer Inc., Novartis AG, Johnson & Johnson, and AstraZeneca PLC.

Fusion Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Fusion Pharmaceuticals Inc. is focused on developing targeted alpha therapies (TAT) for the treatment of cancer. By utilizing its proprietary Targeted Alpha Therapeutics (TAT) platform, Fusion Pharmaceuticals aims to create highly specific radiotherapeutics that deliver alpha particle emitting isotopes directly to cancer cells while sparing healthy tissues. By selectively targeting cancer cells, Fusion Pharmaceuticals seeks to enhance the therapeutic potential and reduce associated toxicity of cancer treatments. Through its innovative TAT platform, Fusion Pharmaceuticals is dedicated to advancing the field of precision oncology and improving outcomes for patients with cancer.

De Fusion Pharmaceuticals K/W is -11,26.

De Fusion Pharmaceuticals KUV is 3.581,94.

De AlleAktien Kwaliteitsscore voor Fusion Pharmaceuticals is 2/10.

De verwachte Fusion Pharmaceuticals omzet is 394.740,00 USD.

De verwachte Fusion Pharmaceuticals winst is -125,61 mln. USD.

Fusion Pharmaceuticals Inc is a biotechnology company specializing in the development of targeted radiation therapies for cancer. The company utilizes an innovative platform technology called bioorthogonal vectors (BOVs) to develop targeted alpha therapies (TAT). TAT is a novel approach in cancer treatment where a radioactive isotope is attached to a specific tumor-specific molecule, allowing the radioactive isotope to be delivered directly to the tumor while sparing the surrounding healthy tissue. Fusion Pharmaceuticals is currently involved in three business areas: TAT discovery and development, preclinical development, and clinical development. TAT discovery and development involve identifying target molecules and creating targeted molecules that bind to these targets. Preclinical development involves preparing the molecules for use in clinical trials. Clinical development involves conducting human studies to evaluate the safety and effectiveness of the product. The main product of Fusion Pharmaceuticals is currently FPX-01, a bovine serum albumin (BSA)-targeted TAT, which is currently being tested in clinical phase I/IIa in patients with advanced pancreatic and breast cancers. However, the company also plans to develop additional products that can treat various types of cancer. Another business area of Fusion Pharmaceuticals is collaborating with other companies to utilize the BOV technology in other applications. For example, the company has announced a collaboration agreement with AstraZeneca to use the BOV technology for targeted radiation therapy of tumors treated with AstraZeneca's immunotherapy products. Fusion Pharmaceuticals' business model relies on a combination of in-house research and development, collaborations with other companies, and raising capital through public offerings. The company has undergone several financing rounds in recent years to fund its research and development. Fusion Pharmaceuticals has also debuted on the NASDAQ stock exchange under the ticker symbol FUSN. Overall, Fusion Pharmaceuticals has garnered significant attention due to its innovative technology and promising clinical results, positioning itself to become a key player in cancer research. The BOV technology and TAT have the potential to revolutionize cancer treatment, and it remains to be seen what the future holds for Fusion Pharmaceuticals.

Fusion Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Fusion Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Fusion Pharmaceuticals is CA36118A1003.

De ticker van Fusion Pharmaceuticals is FUSN.

Binnen de laatste 12 maanden betaalde Fusion Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Fusion Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Fusion Pharmaceuticals is momenteel .

Fusion Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Fusion Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Fusion Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Fusion Pharmaceuticals van 9-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 9-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 9-7-2024.

In het jaar 2023 heeft Fusion Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Fusion Pharmaceuticals worden in USD uitgekeerd.